US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NRIX) オプション

Nurix Therapeutics Inc (NRIX)

23.185

0.725

( 3.23% )

更新日時： 23:34:22

Nurix Therapeutics Inc ([symbol]) オプションチェーン

NRIX ライブオプションフロー

オプションコール

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
13.00	8.00	12.80	4.80	10.40	0.00	0.00 %	0	41	-
14.00	7.00	11.10	8.80	9.05	0.00	0.00 %	0	80	-
15.00	6.00	10.60	4.12	8.30	0.00	0.00 %	0	155	-
16.00	7.00	8.30	7.50	7.65	0.80	11.94 %	2	68	23:09:42
17.00	6.00	7.30	6.96	6.65	4.23	154.95 %	27	260	23:01:07
18.00	3.50	7.10	4.88	5.30	0.00	0.00 %	0	530	-
19.00	2.50	6.40	2.01	4.45	0.00	0.00 %	0	563	-
20.00	3.80	5.90	4.00	4.85	0.50	14.29 %	12	405	23:15:19
21.00	2.70	3.90	3.70	3.30	0.70	23.33 %	4	130	23:16:08
22.00	0.70	4.90	2.75	2.80	0.00	0.00 %	0	11	-
23.00	1.35	4.90	2.50	3.125	0.45	21.95 %	1	8	22:51:15
24.00	0.05	4.90	0.90	2.475	0.00	0.00 %	0	0	-
25.00	1.30	2.85	1.50	2.075	0.10	7.14 %	7	154	23:04:46
26.00	0.35	4.90	0.65	2.625	0.00	0.00 %	0	2	-
27.00	0.10	4.90	0.45	2.50	0.00	0.00 %	0	7	-
28.00	0.05	4.90	0.50	2.475	0.00	0.00 %	0	2	-
29.00	0.00	4.90	1.35	1.35	0.00	0.00 %	0	1	-
30.00	0.00	4.90	1.25	1.25	0.00	0.00 %	0	3	-
35.00	0.00	4.90	0.45	0.45	0.00	0.00 %	0	4	-

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

オプションプット

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
13.00	0.00	4.90	2.50	2.50	0.00	0.00 %	0	6	-
14.00	0.00	0.25	0.95	0.95	0.00	0.00 %	0	14	-
15.00	0.00	4.90	1.82	1.82	0.00	0.00 %	0	27	-
16.00	0.05	4.90	1.10	2.475	0.00	0.00 %	0	11	-
17.00	0.05	4.90	1.48	2.475	0.00	0.00 %	0	6	-
18.00	0.05	4.90	3.10	2.475	0.00	0.00 %	0	2	-
19.00	0.05	4.90	1.70	2.475	0.00	0.00 %	0	4	-
20.00	0.60	4.90	4.90	2.75	0.00	0.00 %	0	2	-
21.00	0.10	4.90	0.00	2.50	0.00	0.00 %	0	0	-
22.00	0.95	4.90	1.50	2.925	-0.15	-9.09 %	3	100	22:44:13
23.00	0.05	4.90	0.00	2.475	0.00	0.00 %	0	0	-
24.00	0.50	4.90	0.00	2.70	0.00	0.00 %	0	0	-
25.00	1.20	5.50	8.50	3.35	0.00	0.00 %	0	0	-
26.00	1.70	6.00	0.00	3.85	0.00	0.00 %	0	0	-
27.00	2.80	7.00	0.00	4.90	0.00	0.00 %	0	0	-
28.00	3.00	7.50	13.18	5.25	0.00	0.00 %	0	0	-
29.00	4.20	8.50	0.00	6.35	0.00	0.00 %	0	0	-
30.00	5.30	9.50	12.75	7.40	0.00	0.00 %	0	0	-
35.00	9.90	14.40	0.00	12.15	0.00	0.00 %	0	0	-

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
INLFINLIF Limited	US$ 0.0547 (82.33%)	1.72B
SDOTSadot Group Inc	US$ 10.88 (76.05%)	17.05M
RCTRedCloud Holdings PLC	US$ 0.4951 (75.01%)	140.4M
IVFINVO Fertility Inc	US$ 2.02 (62.90%)	59.76M
ILLRTriller Group Inc	US$ 4.9001 (60.66%)	48.12M
LICNLichen International Ltd	US$ 1.03 (-38.32%)	11.24M
CRMTAmericas Car Mart Inc	US$ 2.5199 (-33.51%)	1.08M
ANGHAnghami Inc	US$ 3.51 (-32.50%)	78.89k
BTCTBTC Digital Ltd	US$ 0.7962 (-30.16%)	704.89k
SCAGScage Future	US$ 0.462425 (-30.02%)	17.74M
INLFINLIF Limited	US$ 0.0547 (82.33%)	1.72B
GDCGD Culture Group Ltd	US$ 0.0109 (-20.44%)	284.29M
RCTRedCloud Holdings PLC	US$ 0.4951 (75.01%)	140.4M
IVFINVO Fertility Inc	US$ 2.02 (62.90%)	59.76M
PBKPowerBank Corporation	US$ 0.8078 (10.64%)	53.73M

iHub News

iHub News 3月前

Nurix Therapeutics shares edge higher despite Q1 earnings missApril 8, 2026 9:59 AM
IH Market News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported fiscal first-quarter 2026 results on Wednesday that came in below analyst expectations.Despite the miss, the clinical-stage biotech company’s shares rose about 3.06% in pre-market trading as investors focused on the progress of its drug development pipeline and its strong cash reserves.Nurix posted an adjusted loss of $0.79 per share, slightly worse than the consensus forecast of a $0.76 loss. Revenue reached $6.25 million, well below the $14.25 million estimate and down 66% year over year from $18.5 million in the same period last year. The decline was mainly attributed to the expiration of the initial research phase for certain drug targets under the company’s collaboration with Sanofi.The company reported $540.7 million in cash, cash equivalents and marketable securities as of February 28, 2026, compared with $592.9 million at the end of November 2025.“Nurix entered 2026 focused on implementing a comprehensive registrational program designed to establish bexobrutideg as a potential best-in-class medicine for patients with chronic lymphocytic leukemia,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix.Research and development spending increased to $84.1 million from $69.7 million a year earlier, reflecting higher compensation expenses and increased costs related to clinical trials as the company ramps up enrollment in its Phase 2 study of bexobrutideg. General and administrative expenses also rose to $14.6 million from $11.7 million in the same quarter last year.Nurix is currently enrolling patients in its DAYBreak CLL-201 pivotal Phase 2 trial, which is intended to support a potential Accelerated Approval pathway for bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia. The company also plans to begin a global Phase 3 confirmatory study by mid-2026 and is targeting a 2026 IND submission for the drug in inflammatory and autoimmune disease indications.Nurix Therapeutics stock price

Original: Nurix Therapeutics shares edge higher despite Q1 earnings miss

infamous

infamous 9月前

earnings friday morning. im curious

Monksdream

Monksdream 2年前

NRIX 10Q due Oct 17

Monksdream

Monksdream 2年前

NRIX 10 Q due 10 October

Monksdream

Monksdream 2年前

NRIX creeping higher

Monksdream

Monksdream 2年前

NRIX 10 Q expected JULY11

Monksdream

Monksdream 2年前

NRIX new 52 week high

Monksdream

Monksdream 2年前

NRIX more new highs up ahead

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

NRIX new 52 week high

TheFinalCD

TheFinalCD 4年前

https://ih.advfn.com/stock-market/NASDAQ/nurix-therapeutics-NRIX/stock-news/88898489/cathie-wood-doubles-down-on-these-2-strong-buy

infamous

infamous 5年前

what the F is wrong with this fkn stock? does it ever go up???

Phosphene

Phosphene 6年前

CEO: Dr. Arthur T. Sands

https://www.nurixtx.com/arthur-t-sands-m-d-ph-d/

Phosphene

Phosphene 6年前

Strategic partnerships with Sanofi and Gilead Sciences Inc.

https://www.nurixtx.com/research-development/strategic-partnerships/

Wellington and Baker Brothers are among Institutional Ownership and Shareholders:

https://fintel.io/so/us/nrix?__cf_chl_jschl_tk__=c9a7439112376e9f70de91c1316dfcc7e26d3519-1607403189-0-AT-0XpHMlNGWmcEzimwDKelDxLnOK6gsd8IihalGD8DcDe76KQlrWnh2Q1G3OLjfsidXSQyjVOkcCg3lXIXgKu6RIlw8DMusjRJpgnTzQP2qkahd1WSCP-5At2BI9Udfzc2vqpmlZOV3prAMIdFIh1_urJuBNq7hGlM4oSEJKFEFs8WDerUagukeDe9yBmvVg0Ne17vR8ByRaN-BlyHHxPWeTerJ_ZHoD1jnsxFYInhjhkK-XNkhe3BJ0Wzq3782kDVndNMNsb1glMkmm_NlSnc8Xbwve1nF3nGShcpgUxA-nefEgd9L74SzGXF1WftTIX4HYgwtb1BRzq82RClNfm9dr9Xb-hKp3xKKiYL4k9KfqV9OAePxDJoYgKqLUziXoA

Phosphene

Phosphene 6年前

Data support a planned clinical trial of NX-2127 in B-cell malignancies

http://www.globenewswire.com/news-release/2020/12/07/2140737/0/en/Nurix-Therapeutics-Presents-Preclinical-Data-at-62nd-American-Society-of-Hematology-ASH-Annual-Meeting-and-Exposition.html

Nurix Therapeutics

Visionary Metals

100.00% 25/02/29 100.00%...

Innovative Industrial Pr...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。